Tenaya Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Tenaya Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q3 2024.
  • Tenaya Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$25.6M, a 12% increase year-over-year.
  • Tenaya Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$117M, a 8.18% increase year-over-year.
  • Tenaya Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$124M, a 0.34% decline from 2022.
  • Tenaya Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$124M, a 70.1% decline from 2021.
  • Tenaya Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$72.7M, a 89.4% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$117M -$25.6M +$3.51M +12% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 -$121M -$29.4M +$3.84M +11.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-06
Q1 2024 -$125M -$32.2M -$491K -1.55% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-06
Q4 2023 -$124M -$29.9M +$3.58M +10.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-18
Q3 2023 -$128M -$29.1M +$1.55M +5.06% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 -$129M -$33.3M -$4.87M -17.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-06
Q1 2023 -$124M -$31.7M -$681K -2.19% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-06
Q4 2022 -$124M -$33.5M -$7.37M -28.2% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-18
Q3 2022 -$116M -$30.7M -$12.4M -68.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$104M -$28.4M -$13.2M -86.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-08
Q1 2022 -$90.7M -$31.1M -$18M -137% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-08
Q4 2021 -$72.7M -$26.2M -$15.8M -153% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-08
Q3 2021 -$56.9M -$18.3M -$7.97M -77.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$48.9M -$15.2M -$6.48M -74.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-10
Q1 2021 -$42.4M -$13.1M -$4.05M -44.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-10
Q4 2020 -$38.4M -$10.3M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-23
Q3 2020 -$10.3M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$8.73M Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-10
Q1 2020 -$9.05M Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.